Supramolecular gelator, in-situ gelation apoptotic cell derivative, and preparation method and application of supramolecular gelator and in-situ gelation apoptotic cell derivative
Caspase enzymatic self-assembly supramolecular gel factor forms nanofibers and gel in situ in apoptotic cells, solving the problems of low stability of derivatives and low retention of biologically active substances in engineered apoptotic cells, achieving more Good treatment effect.
Patent Information
- Application Number
- CN202411042880.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
The existing engineered apoptotic cell derivatives have shortcomings in stability and retention of biologically active substances, resulting in unsatisfactory treatment results.
Design and synthesize Caspase enzymatic self-assembled supramolecular gel factor, and through the connection of specific peptide sequences and hydrophobic drugs, the expression characteristics of Caspase enzyme in apoptotic cells are used to form nanofibers and gel in situ to improve apoptosis. Mechanical strength of cell derivatives and retention of biologically active substances.
Improve the stability of apoptotic cell derivatives and the retention rate of biologically active substances, realize the intracellular targeted delivery of hydrophobic drugs and synergistically with biologically active substances, and significantly improve the treatment of cardiovascular, skin, joints and other diseases. Effect.
Smart Images

Figure BDA0004972807700000011 
Figure BDA0004972807700000021 
Figure BDA0004972807700000051
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a supramolecular gel factor, an in situ gelled apoptotic cell derivative, and a preparation method and application thereof. Background Art
[0002] With the development of cell therapy and cell-free therapy, cell derivatives such as engineered cells and engineered extracellular vesicles have been widely studied. In recent years, the research on apoptosis has become more in-depth, and apoptotic cell derivatives have received widespread attention and have been proven to have therapeutic effects in cardiovascular, skin and other related diseases. At present, the engineering method based on apoptotic cell derivatives is mainly mechanical extrusion, which has the advantage of controllable size, but still has shortcomings such as poor stability and low retention rate of bioactive substances.
[0003] Peptide-based supramolecules are an emerging type of nanobiomaterial that can self-assemble in response to specific stimuli to form complex structures including nanofibers. Specially designed supramolecules can also form gels. Peptide-based supramolecules have the advantages of simple synthesis and controllable structure. The design of new supramolecules and the expansion of their application range have been one of the research hotspots in recent years.
[0004] There are no reports on the application of supramolecular materials in the engineering of apoptotic cell derivatives. Summary of the invention
[0005] Based on this, the present invention provides an in situ gelled apoptotic cell derivative, which improves the stability of the apoptotic cell derivative and the retention rate of bioactive substances.
[0006] The present invention includes the following technical solutions.
[0007] In a first aspect, the present invention provides a polypeptide that can be used to prepare a supramolecular gel factor, wherein the amino acid sequence is 2 N-Gly-Gly-Gly-His-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH or H 2 N-Val-Val-Ala-Gly-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH.
[0008] In a second aspect, the present invention provides a supramolecular gel factor, which is obtained by connecting the polypeptide of the present invention to a hydrophobic drug, and has the following structural formula:
[0009]
[0010]
[0011] Herein, Drug refers to a hydrophobic drug.
[0012] Wherein, the hydrophobic drug can be atorvastatin, lauric acid, all-trans retinoic acid or adapalene.
[0013] In a third aspect, the present invention provides a method for preparing the supramolecular gelator, comprising the following steps:
[0014] The hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are dissolved in an organic solvent and stirred for reaction; then the polypeptide is added and stirred for reaction to obtain;
[0015] Preferably, the molar ratio of the hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is 1:1.5-2.5:1.5-2.5; the molar ratio of the hydrophobic drug or its salt and the polypeptide is 1-1.2:1; and the organic solvent is dimethyl sulfoxide.
[0016] In a fourth aspect, the present invention provides an in situ gelled apoptotic cell derivative, which is prepared from apoptotic cells or apoptotic cell extracellular vesicles and the supramolecular gelator of the present invention;
[0017] The apoptotic cells or extracellular vesicles contain biologically active substances with therapeutic effects;
[0018] The supramolecular gelator is gelled in situ inside the apoptotic cells or apoptotic cell extracellular vesicles to form an inner core.
[0019] Wherein, the apoptotic cells or apoptotic extracellular vesicles are obtained by inducing apoptosis of mammalian cells in vitro and then separating them by centrifugation; the in vitro cells are mesenchymal stem cells, macrophages, T lymphocytes, endothelial cells, chondrocytes, or cancer cells; the ratio of the supramolecular gel factor to the apoptotic cells or apoptotic extracellular vesicles is 0.001 μmol-0.1 μmol: 100 μg, preferably 0.01 μmol-0.06 μmol: 100 μg, and more preferably 0.03 μmol-0.05 μmol: 100 μg.
[0020] In a fifth aspect, the present invention provides a method for preparing the in situ gelled apoptotic cell derivative, comprising the following steps:
[0021] The supramolecular gel factor is dissolved in a phosphate buffer, and then the apoptotic cells or apoptotic extracellular vesicles are added and incubated to obtain the product.
[0022] In a sixth aspect, the present invention provides the use of the in situ gelled apoptotic cell derivative in the preparation of a drug for treating a disease, wherein the disease is a cardiovascular, skin or joint-related disease.
[0023] The specific disease depends on the hydrophobic drug connected to the gel factor and / or the bioactive substance contained in the apoptotic cells or extracellular vesicles. For example, when the drug connected to the supramolecular gel factor is atorvastatin, the disease is non-alcoholic fatty liver disease.
[0024] In a seventh aspect, the present invention further provides a pharmaceutical composition prepared from the in situ gelled apoptotic cell derivative described in the present invention and pharmaceutically acceptable excipients.
[0025] The beneficial effects of the present invention are as follows:
[0026] The present invention utilizes the up-regulated expression of Caspase enzyme in apoptotic cell derivatives, designs and synthesizes a Caspase enzymatic self-assembly supramolecular gel factor, the supramolecular gel factor comprises a polypeptide of a specific sequence, and a hydrophobic drug is connected at one end thereof, which can enter and exit the cell membrane by diffusion, and after entering the apoptotic cell derivative, can self-assemble to form nanofibers under the action of Caspase enzyme, and further gel in situ to form a core, thereby obtaining an in situ gelled apoptotic cell derivative. The present invention utilizes the up-regulated expression of Caspase enzyme in apoptotic cell derivatives, and for the first time applies Caspase enzymatic self-assembly supramolecular materials to the engineering of apoptotic cell derivatives, improves the mechanical strength of apoptotic cell derivatives through internal in situ gelation, slows down its internal biochemical reaction, thereby improving the stability of apoptotic cell derivatives and the retention rate of bioactive substances; at the same time, it can be used as a carrier of hydrophobic drugs, can effectively realize the intracellular targeted delivery of hydrophobic drugs, and play a synergistic role with the bioactive substances in apoptotic cell derivatives, improve the therapeutic effect, and provide a new treatment strategy for cardiovascular, skin, joint and other related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is the ESI-MS mass spectrum of the polypeptide GGGHDEVDDRRRR prepared in Example 1.
[0028] Figure 2 This is the HPLC chromatogram of the polypeptide GGGHDEVDDRRRR prepared in Example 1.
[0029] Figure 3 This is the ESI-MS mass spectrum of the supramolecular gel factor (lauric acid)-VVAGDEVDDRRRR in Example 2.
[0030] Figure 4This is the HPLC chromatogram of the supramolecular gel factor (lauric acid)-VVAGDEVDDRRRR in Example 2.
[0031] Figure 5 is the supramolecular gel factor (lauric acid)-GGGHDEVDDRRRR in Example 3 1 H-NMR nuclear magnetic resonance hydrogen spectrum.
[0032] Figure 6 is the supramolecular gel factor (atorvastatin)-VVAGDEVDDRRRR in Example 3 1 H-NMR nuclear magnetic resonance hydrogen spectrum.
[0033] Figure 7 is the supramolecular gel factor (lauric acid)-VVAGDEVDDRRRR in Example 3 1 H-NMR nuclear magnetic resonance hydrogen spectrum.
[0034] Figure 8 is the supramolecular gel factor (all-trans retinoic acid)-VVAGDEVDDRRRR in Example 3 1 H-NMR nuclear magnetic resonance hydrogen spectrum.
[0035] Fig. 9 is the supramolecular gel factor (adapalene)-VVAGDEVDDRRRR in Example 3 1 H-NMR nuclear magnetic resonance hydrogen spectrum.
[0036] Fig.10 This is the fluorescent image of cell apoptosis in Example 4.
[0037] Fig.11 This is the dynamic light scattering result of the supramolecular gel factor (lauric acid)-VVAGDEVDDRRRR after enzymatic self-assembly in Example 5.
[0038] Fig.12 This is a transmission electron microscope image of the supramolecular gel factor after enzymatic self-assembly in Example 5.
[0039] Fig.13 This is the flow cytometric analysis result of apoptotic cells and apoptotic extracellular vesicles in Example 6.
[0040] Fig.14 This is a fluorescent image of apoptotic cells gelled in situ in Example 7.
[0041] Fig.15 These are scanning electron microscopy images of the in situ gelled apoptotic extracellular vesicles in Example 8 under different treatment conditions.
[0042] Fig.16Hematoxylin & eosin staining and Oil Red O staining of liver pathological sections after the in situ gelled apoptotic extracellular vesicles were used to treat non-alcoholic fatty liver disease in mice in Example 9. DETAILED DESCRIPTION
[0043] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0044] The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions, such as the fourth edition of Molecular Cloning: A Laboratory Manual edited by Green and Sambrook, published in 2013, or according to the conditions recommended by the manufacturer. The various commonly used chemical reagents used in the examples are all commercially available products.
[0045] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.
[0046] In addition, as used in the present invention, the term "or" is an inclusive "or" symbol and is equivalent to the term "and / or", unless the context clearly dictates otherwise. The term "based on" is not exclusive and allows for being based on other factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meanings of "a", "an", and "the" include plural referents. The meaning of "in..." includes "in..." and "on...".
[0047] In order to solve the problems of poor stability, low retention rate of bioactive substances, and unsatisfactory therapeutic effect of apoptotic cell derivatives prepared by existing engineering methods, the present invention provides a non-destructive and simple engineering method. The method synthesizes a polypeptide of a specific sequence and connects a hydrophobic drug at one end thereof to prepare a class of supramolecular gel factors, which can enter and exit the cell membrane by diffusion, and after entering the apoptotic cell derivative, can self-assemble to form nanofibers under the action of Caspase, and further gel in situ to form a core, thereby preparing an apoptotic cell derivative with in situ gelation. The present invention utilizes the characteristic of up-regulated expression of Caspase enzymes in apoptotic cell derivatives, and for the first time applies Caspase enzymatic self-assembly supramolecular materials to the engineering of apoptotic cell derivatives. The mechanical strength of the apoptotic cell derivatives is improved and the internal biochemical reactions are slowed down through internal in situ gelation, thereby improving the stability of the apoptotic cell derivatives and the retention rate of bioactive substances. At the same time, it can be used as a carrier of hydrophobic drugs, can effectively achieve intracellular targeted delivery of hydrophobic drugs, and exert a synergistic effect with the bioactive substances in the apoptotic cell derivatives to improve the therapeutic effect, providing a new treatment strategy for cardiovascular, skin, joint and other related diseases.
[0048] In one embodiment of the present invention, a polypeptide is provided which can be used to prepare a supramolecular gel factor, and its amino acid sequence is H 2 N-Gly-Gly-Gly-His-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH or H 2 N-Val-Val-Ala-Gly-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH.
[0049] In another embodiment of the present invention, a supramolecular gelator is provided, which is obtained by connecting the polypeptide of the present invention to a hydrophobic drug, and has the following structural formula:
[0050]
[0051] Herein, Drug refers to a hydrophobic drug.
[0052] The supramolecular gel factor of the present invention has a hydrophobic drug connected to one end of the polypeptide, which can be recognized and sheared by Caspase enzyme, self-assembled to form nanofibers, and further gelled.
[0053] In some embodiments, the hydrophobic drug is atorvastatin, lauric acid, all-trans retinoic acid or adapalene.
[0054] In some embodiments, the structural formula of the supramolecular gelator is as follows:
[0055]
[0056]
[0057] In another embodiment of the present invention, a method for preparing the supramolecular gel factor is provided, comprising the following steps:
[0058] The hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are dissolved in an organic solvent and stirred for reaction; then the polypeptide is added and stirred for reaction to obtain the product.
[0059] In some embodiments, the method for preparing the supramolecular gelator comprises the following steps:
[0060] The hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are dissolved in an organic solvent, stirred at room temperature for reaction for 3-6 hours; then the polypeptide is added, stirred at room temperature for reaction for 3-9 hours to obtain the product.
[0061] In some embodiments, the method for preparing the supramolecular gelator comprises the following steps:
[0062] The hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are dissolved in an organic solvent, stirred at room temperature for 5-6 hours; then the polypeptide is added, stirred at room temperature for 6-8 hours to obtain the product.
[0063] The room temperature described in the present invention refers to an indoor temperature of 15°C-35°C.
[0064] In some embodiments, the molar ratio of the hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is 1:1.5-2.5:1.5-2.5.
[0065] In some embodiments, the molar ratio of the hydrophobic drug or its salt to the polypeptide is 1-1.2:1.
[0066] In some embodiments, the organic solvent is dimethyl sulfoxide.
[0067] In some of the embodiments, the method for preparing the supramolecular gelator further comprises the following post-treatment step: dialyzing the reaction mixture in deionized water using a 1000Da dialysis bag and freeze-drying.
[0068] In another embodiment of the present invention, there is provided an in situ gelled apoptotic cell derivative, which is prepared from apoptotic cells or apoptotic extracellular vesicles and the supramolecular gelator of the present invention;
[0069] The apoptotic cells or extracellular vesicles contain biologically active substances with therapeutic effects;
[0070] The supramolecular gelator is gelled in situ inside the apoptotic cells or apoptotic cell extracellular vesicles to form an inner core.
[0071] In some embodiments, the apoptotic cells or apoptotic extracellular vesicles are obtained by inducing apoptosis of mammalian cells in vitro and then separating them by centrifugation.
[0072] The induction method may be a conventional method known to technicians. Preferably, the cells are cultured until the cell confluence in the culture vessel reaches more than 80%, and then treated with 0.5-2 μM staurosporine for 3-12 hours to induce cell apoptosis.
[0073] Centrifugal separation is also a conventional method well known to those skilled in the art, and preferably includes the following steps: digesting the cells with a trypsin solution having a concentration of 0.2%-0.3% (w / w) to release the cells from the wall, centrifuging at 200-400 g for 3-8 minutes to separate the apoptotic cells, and further centrifuging the supernatant at 900-1100 g for 3-8 minutes to remove cell debris, and finally centrifuging the supernatant at 10,000-21,000 g (preferably 11,000-13,000 g) for 60-120 minutes to separate the apoptotic cell extracellular vesicles.
[0074] In some embodiments, the ex vivo cells are mesenchymal stem cells, macrophages, T lymphocytes, endothelial cells, chondrocytes, or cancer cells.
[0075] In some embodiments, the apoptotic extracellular vesicles include apoptotic bodies and apoptotic microvesicles.
[0076] In some embodiments, the ratio of the supramolecular gelator to the apoptotic cells or apoptotic extracellular vesicles is 0.001 μmol-0.1 μmol:100 μg, preferably 0.01 μmol-0.1 μmol:100 μg, and more preferably 0.03 μmol-0.05 μmol:100 μg.
[0077] In one embodiment of the present invention, a method for preparing the in situ gelled apoptotic cell derivative is also provided, comprising the following steps:
[0078] The supramolecular gel factor and the apoptotic cells or the apoptotic extracellular vesicles are incubated in a phosphate buffer to obtain the product.
[0079] In some embodiments, the concentration of the supramolecular gelator in phosphate buffer is 10 μM-50 μM, preferably 15 μM-25 μM.
[0080] In some embodiments, the pH of the phosphate buffer is 7.3-7.5.
[0081] In some embodiments, the concentration of the apoptotic cells or apoptotic extracellular vesicles in phosphate buffer is 30 μg / mL-100 μg / mL, preferably 40 μg / mL-60 μg / mL.
[0082] In some embodiments, the incubation temperature and time are: 35° C.-40° C. for 3-6 hours.
[0083] In some embodiments, the method for preparing the in situ gelled apoptotic cell derivatives also includes a centrifugation separation step, for example, preferably includes the following steps: centrifugation at 200-400g for 3-8 minutes to separate the in situ gelled apoptotic cells; centrifugation at 12,000-21,000g (preferably 15000-16000g) for 60-120 minutes to separate the in situ gelled apoptotic cell extracellular vesicles.
[0084] The in situ gelled apoptotic cell derivatives of the present invention can improve the mechanical strength of the apoptotic cell derivatives and slow down their internal biochemical reactions, thereby improving the stability of the apoptotic cell derivatives and the retention rate of bioactive substances; at the same time, they can be used as carriers of hydrophobic drugs, effectively achieve intracellular targeted delivery of hydrophobic drugs, and play a synergistic role with the bioactive substances in the apoptotic cell derivatives to improve the therapeutic effect, providing a new treatment strategy for cardiovascular, skin, joint and other related diseases.
[0085] For example, when the drug connected to the supramolecular gel factor is atorvastatin, the prepared in situ gelled apoptotic cell derivative has a good therapeutic effect on non-alcoholic fatty liver disease, and its therapeutic effect is significantly better than that of atorvastatin, that is, it can significantly improve the therapeutic effect of the drug itself.
[0086] In another embodiment of the present invention, a pharmaceutical composition is provided, which is prepared from the in situ gelled apoptotic cell derivative of the present invention and an excipient acceptable in medicine.
[0087] The pharmaceutical composition can be administered to patients via various routes of administration, including but not limited to oral, transdermal, intramuscular, subcutaneous and intravenous injection.
[0088] Examples of acceptable excipients in drugs: cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0089] The present invention is further described in detail below with reference to specific embodiments.
[0090] Example 1
[0091] Peptide H 2 The solid phase synthesis of N-Gly-Gly-Gly-His-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH specifically comprises the following steps:
[0092] (1) Weigh n equivalents of resin and place them in a reactor. Add dichloromethane to swell for 0.5 hours, then remove the dichloromethane. Add 2n equivalents of arginine, the first amino acid in the sequence, from the C-terminal arginine to the N-terminal glycine. Add 2n equivalents of diisopropylethylamine. Slowly add N,N-dimethylformamide and dichloromethane until the resin is fully agitated. Bubble nitrogen for reaction for 1 hour, then add 5n equivalents of methanol. Continue to react for 0.5 hours. Remove the reaction solvent and wash with N,N-dimethylformamide and methanol.
[0093] (2) Add 2n equivalents of arginine, the second amino acid in the sequence, to the reactor, add 2n equivalents of 1-hydroxybenzotrichloridoxazole tetramethyl hexafluorophosphate and 2n equivalents of diisopropylethylamine, react with nitrogen bubbling for 0.5 hours, remove the reaction solution, and detect with ninhydrin. Then cap with 20% (v / v) pyridine and 20% (v / v) acetic anhydride. Finally, wash, add an appropriate amount of decapping liquid to remove the 9-fluorenylmethoxycarbonyl protecting group, wash, and detect with ninhydrin.
[0094] (3) Repeat the above steps and add different amino acids in the sequence in sequence.
[0095] (4) Finally, the resin was blown dry with nitrogen and removed from the reaction column, poured into a flask, and then a cutting solution (95% trifluoroacetic acid, 2% ethanedithiol, 2% triisopropylsilane, 1% water) was added at 10 mL / g, shaken, and filtered to remove the resin. A filtrate was obtained, and then a large amount of ether was added to the filtrate until a crude product was precipitated, centrifuged, and washed to obtain a crude product of the sequence.
[0096] (5) The crude product was purified to 95% by high performance liquid chromatography. The purified liquid was concentrated by freeze drying to obtain a white powder, i.e., a compound with the sequence H 2 A polypeptide of N-Gly-Gly-Gly-His-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH.
[0097] like Figure 1 and Figure 2 As shown, the ESI-MS mass spectrum and HPLC chromatography results showed that the target product was obtained.
[0098] Example 2
[0099] The synthesis of supramolecular gel factor (lauric acid)-Val-Val-Ala-Gly-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH specifically comprises the following steps:
[0100] (1) Weigh n equivalents of resin and place them in a reactor. Add dichloromethane to swell for 0.5 hours, then remove the dichloromethane. Add 2n equivalents of arginine, the first amino acid in the sequence, from the C-terminal arginine to the N-terminal valine. Add 2n equivalents of diisopropylethylamine. Slowly add N,N-dimethylformamide and dichloromethane until the resin is fully agitated. Bubble nitrogen for reaction for 1 hour, then add 5n equivalents of methanol. Continue to react for 0.5 hours. Remove the solvent of the reaction solution and wash with N,N-dimethylformamide and methanol.
[0101] (2) Add 2n equivalents of arginine, the second amino acid in the sequence, to the reactor, add 2n equivalents of 1-hydroxybenzotrichloridoxazole tetramethyl hexafluorophosphate and 2n equivalents of diisopropylethylamine, react with nitrogen bubbling for 0.5 hours, remove the reaction solution, and detect with ninhydrin. Then cap with 20% (v / v) pyridine and 20% (v / v) acetic anhydride. Finally, wash, add an appropriate amount of decapping liquid to remove the 9-fluorenylmethoxycarbonyl protecting group, wash, and detect with ninhydrin.
[0102] (3) Repeat the above steps and add different amino acids in the sequence in sequence.
[0103] (4) Finally, the resin was blown dry with nitrogen and removed from the reaction column, poured into a flask, and then a cutting solution (95% trifluoroacetic acid, 2% ethanedithiol, 2% triisopropylsilane, 1% water) was added at 10 mL / g, shaken, and filtered to remove the resin. A filtrate was obtained, and then a large amount of ether was added to the filtrate until a crude product was precipitated, centrifuged, and washed to obtain a crude product of the sequence.
[0104] (5) The crude product was purified to 95% by high performance liquid chromatography. The purified liquid was concentrated by freeze drying to obtain a white powder, i.e., a compound with the sequence H2 A polypeptide of N-Val-Val-Ala-Gly-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH.
[0105] (6) Weigh n equivalents of lauric acid, 2n equivalents of N-hydroxysuccinimide and 2n equivalents of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, dissolve them in dimethyl sulfoxide, and stir at room temperature for 6 hours; then add n equivalents of the above-mentioned crude polypeptide product, and stir at room temperature for 6 hours.
[0106] (7) The purified solution was dialyzed in deionized water using a 1000 Da dialysis bag and freeze-dried to obtain a white powder.
[0107] like Figure 3 and Figure 4 As shown, the ESI-MS mass spectrum and HPLC chromatography results showed that the target product was obtained.
[0108] Example 3
[0109] The synthesis of supramolecular gel factor specifically comprises the following steps:
[0110] (3) Weigh n equivalents of atorvastatin calcium or lauric acid or all-trans retinoic acid or adapalene, 2n equivalents of N-hydroxysuccinimide and 2n equivalents of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, dissolve them in dimethyl sulfoxide, and react at room temperature with stirring for 6 hours.
[0111] (4) Then add n equivalents of the sequence H 2 N-Val-Val-Ala-Gly-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH or H 2 The crude polypeptide product of N-Gly-Gly-Gly-His-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH was stirred at room temperature for 6 hours.
[0112] (5) The purified liquid was dialyzed in deionized water using a 1000 Da dialysis bag and freeze-dried to obtain a powder.
[0113] As attached Figure 5-Figure 9 As shown, 1 The results of H-NMR nuclear magnetic resonance hydrogen spectrum show that the target product is obtained. Its structural formula is as follows:
[0114]
[0115]
[0116] Example 4
[0117] The induction of apoptosis of mammalian cells in vitro specifically includes the following steps:
[0118] (1) The culture medium used for mouse RAW264.7 cells included 89% (v / v) Dulbecco's modified Eagle's medium, 10% (v / v) fetal bovine serum, and 1% (v / v) penicillin and streptomycin.
[0119] (2) Mouse RAW264.7 cells were inoculated in a culture dish and cultured at 37°C and 5% carbon dioxide. When the confluence reached more than 80%, they were treated with 1 μM staurosporine for 3-6 hours to induce macrophage apoptosis.
[0120] (3) Aspirate the liquid in the culture dish, add Annexin V binding buffer, Annexin V-APC stain, and Caspase 3 stain, and continue incubating at 37°C for 30 min. Take fluorescence images using a confocal microscope.
[0121] like Fig.10 As shown, the results showed that the induced cells had a high expression level of Caspase3 enzyme, which is characteristic of apoptosis, and phosphatidylserine was flipped to the outside of the membrane.
[0122] Example 5
[0123] This example tests the enzymatic self-assembly function of the supramolecular gelator, which specifically includes the following steps:
[0124] (1) The apoptotic cells of Example 4 were resuspended in deionized water and repeatedly frozen and thawed between -20°C and room temperature. A clear apoptotic cell lysate solution was obtained by filtering with a 0.22 μm filter membrane, and then diluted with deionized water to 100 μg / mL.
[0125] (2) The synthesized peptide VVAGDEVDDRRRR or supramolecular gel factor (Lauryl
[0126] Acid)-GGGHDEVDDRRRR or (atorvastatin)-VVAGDEVDDRRRR or (lauric acid)-VVAGDEVDDRRRR or (all-trans retinoic acid)-VVAGDEVDDRRRR or (adapalene)-VVAGDEVDDRRRR were ultrasonically dissolved in deionized water to obtain a polypeptide solution with a concentration of 1 mg / mL or a corresponding supramolecular gel factor solution.
[0127] (3) The polypeptide solution or supramolecular gel factor solution was mixed with the apoptotic cell lysate solution and incubated at 37° C. for 3 hours.
[0128] (4) Use a particle size analyzer based on dynamic light scattering to directly measure the particle size in the mixed solution. Drop the mixed solution onto a carbon-coated copper mesh, let it stand, remove excess liquid, negatively stain with a phosphotungstic acid solution, wash with deionized water, dry, and then take an image using a transmission electron microscope with a voltage set to 120 kV.
[0129] like Fig.11 As shown, the results show that the peptide VVAGDEVDDRRRR prepared by the present invention did not undergo significant changes within 3 hours under the action of Caspase, while the size of (lauric acid)-VVAGDEVDDRRRR increased significantly within 3 hours under the action of Caspase.
[0130] like Fig.12 As shown, the results show that the supramolecular gel factor prepared by the present invention can self-assemble to form flexible nanofibers under the action of Caspase enzyme.
[0131] Example 6
[0132] The separation of apoptotic cell derivatives specifically comprises the following steps:
[0133] (1) After inducing apoptosis, the macrophages cultured adherently in Example 4 were digested with 0.25% trypsin solution to release the adherence.
[0134] (2) Centrifuge at 300 g for 5 minutes to separate apoptotic macrophages.
[0135] (3) The supernatant was centrifuged at 1000 g for 5 min to remove cell debris. The supernatant was finally centrifuged at 12,000 g for 60 min to isolate macrophage-derived apoptotic extracellular vesicles.
[0136] (4) Annexin V binding buffer and Annexin V were added to the apoptotic extracellular vesicle suspension for fluorescent labeling. After incubation at 37°C for 30 minutes, unbound Annexin V was removed by centrifugation at 12,000 g for 60 minutes, and the proportion of apoptotic extracellular vesicles with fluorescent signals was analyzed using flow cytometry.
[0137] like Fig.13 The results showed that apoptotic extracellular vesicles have the same characteristic of phosphatidylserine flipping to the outer side of the membrane as apoptotic cells.
[0138] Example 7
[0139] The preparation of in situ gelled apoptotic cell derivatives specifically comprises the following steps:
[0140] (1) The supramolecular gelator (lauric acid)-VVAGDEVDDRRRR was dissolved by ultrasonication in a phosphate buffer having a pH of 7.3-7.5 at 25°C to obtain a 50 μM supramolecular gelator solution.
[0141] (2) The apoptotic macrophages isolated in Example 6 were diluted with a phosphate buffer solution with a pH of 7.3-7.5 to a concentration of 100 μg / mL, and 1 mL was mixed with 1 mL of the supramolecular gel factor solution in equal volumes and incubated at 37° C. for 3 hours. Hoechst 33342, FITC, and DiD fluorescent dyes were added at the same time to label the cell nucleus, cytoplasm, and cell membrane, respectively.
[0142] (3) Centrifuge at 300 g for 5 minutes to separate the apoptotic macrophages with internal gelation.
[0143] The apoptotic macrophages in step (2) were replaced with normal cells and incubated with the supramolecular gel factor in the same manner as a control.
[0144] The apoptotic macrophages with internal gelation and the normal cells after incubation with the supramolecular gelator were treated with 10% Triton X-100 for 30 minutes to dissolve the cell membrane and verify the in situ gelation inside the apoptotic cells.
[0145] (4) Fluorescence images were taken using a confocal microscope.
[0146] like Fig.14 As shown, the results indicate that normal cells incubated with supramolecular gel factors lose their cell membrane and cannot maintain their cell morphology, while supramolecular gel factors can penetrate the cell membrane and enter the apoptotic cells after incubation with apoptotic macrophages, and form in situ gel under the action of Caspase enzyme, so that the apoptotic cells incubated with supramolecular gel factors can still maintain their cell morphology after losing their cell membrane.
[0147] Example 8
[0148] The preparation of in situ gelled apoptotic extracellular vesicles specifically comprises the following steps:
[0149] (1) The supramolecular gelator (lauric acid)-VVAGDEVDDRRRR or (atorvastatin)-VVAGDEVDDRRRR was sonicated at 25° C. in a phosphate buffer having a pH of 7.3-7.5 to obtain a supramolecular gelator solution having a concentration of 30 μM.
[0150] (2) The apoptotic extracellular vesicles derived from macrophages isolated in Example 6 were diluted with a phosphate buffer solution having a pH of 7.3-7.5 to a solution having a concentration of 100 μg / mL, and 1 mL of the solution was mixed with 1 mL of the supramolecular gel factor solution in equal volumes and incubated at 37° C. for 6 hours.
[0151] (3) Centrifugation at 16,000 g for 60 min was performed to isolate macrophage-derived apoptotic extracellular vesicles with internal gelation.
[0152] Stability test: The internally gelled macrophage-derived apoptotic extracellular vesicles and the macrophage-derived apoptotic extracellular vesicles separated in Example 6 were resuspended in fetal bovine serum and placed on a shaker at 37°C for 7 days; or resuspended in ultrapure water and repeatedly frozen and thawed for 10 cycles at -20°C to room temperature. The morphological characteristics of the in situ gelled apoptotic extracellular vesicles and the natural apoptotic extracellular vesicles were observed using a scanning electron microscope.
[0153] As attached Fig.15 As shown, natural apoptotic extracellular vesicles cannot maintain their original morphology after the above treatment, while the in situ gelled apoptotic extracellular vesicles can still maintain their basic morphology after the above treatment, proving that the in situ gelled apoptotic extracellular vesicles prepared by the supramolecular gel factor and apoptotic extracellular vesicles of the present invention can improve the stability of the apoptotic extracellular vesicles.
[0154] Example 9
[0155] This example tests the therapeutic effect of in situ gelled apoptotic extracellular vesicles on non-alcoholic fatty liver disease in mice.
[0156] (1) At 25° C., the supramolecular gelator (atorvastatin)-VVAGDEVDDRRRR was ultrasonically dissolved in a phosphate buffer having a pH of 7.3-7.5 to obtain a supramolecular gelator solution having a concentration of 30 μM.
[0157] (2) The apoptotic extracellular vesicles derived from macrophages isolated in Example 6 were diluted with a phosphate buffer solution having a pH of 7.3-7.5 to a solution having a concentration of 100 μg / mL, and 1 mL of the solution was mixed with 1 mL of the supramolecular gel factor solution in equal volumes and incubated at 37° C. for 6 hours.
[0158] (3) Centrifugation at 16,000 g for 60 min was performed to isolate macrophage-derived apoptotic extracellular vesicles with internal gelation.
[0159] (4) C57BL / 6 mice were fed a high-fat diet containing 60% fat for 12 weeks, and the mice developed fatty liver symptoms, thus establishing a non-alcoholic fatty liver mouse model. The mice were randomly divided into four groups: normal saline group, atorvastatin group, apoptotic extracellular vesicle group, and gelled apoptotic extracellular vesicle group. Healthy mice fed with ordinary feed were used as the blank control group.
[0160] (5) 200 μL of normal saline, 5 mg / kg body weight of atorvastatin, 5 mg / kg body weight of macrophage-derived apoptotic extracellular vesicles, and 5 mg / kg body weight of internally gelled macrophage-derived apoptotic extracellular vesicles were injected into non-alcoholic fatty liver mice through the tail vein, twice a week (200 μL each time) for a total of 6 weeks.
[0161] (6) The mouse liver was taken for pathological sectioning and stained with hematoxylin & eosin and oil red O.
[0162] As attached Fig.16 As shown, atorvastatin and natural apoptotic extracellular vesicles alleviated fat deposition and fibrosis in the mouse liver, while in situ gelled apoptotic extracellular vesicles showed better therapeutic effects, demonstrating that in situ gelled apoptotic extracellular vesicles can be used as drug carriers to enhance the therapeutic ability of hydrophobic drugs and natural apoptotic extracellular vesicles.
[0163] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A polypeptide that can be used to prepare a supramolecular gel factor, It is characterized in that Its amino acid sequence is H 2 N-Gly-Gly-Gly-His-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH or H 2 N-Val-Val-Ala-Gly-Asp-Glu-Val-Asp-Asp-Arg-Arg-Arg-Arg-COOH.
2. A supramolecular gel factor, It is characterized in that It is obtained by connecting the polypeptide according to claim 1 to a hydrophobic drug, and its structural formula is as follows: Herein, Drug refers to a hydrophobic drug.
3. The supramolecular gel factor according to claim 2, It is characterized in that The hydrophobic drug is atorvastatin, lauric acid, all-trans retinoic acid or adapalene.
4. The supramolecular gel factor according to claim 3, It is characterized in that The structural formula of the supramolecular gel factor is as follows:
5. A method for preparing the supramolecular gelator according to any one of claims 2 to 4, It is characterized in that The steps include: The hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride are dissolved in an organic solvent and stirred for reaction; then the polypeptide is added and stirred for reaction to obtain; Preferably, the molar ratio of the hydrophobic drug or its salt, N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is 1:1.5-2.5:1.5-2.5; Preferably, the molar ratio of the hydrophobic drug or its salt to the polypeptide is 1-1.2:1; Preferably, the organic solvent is dimethyl sulfoxide.
6. An in situ gelled apoptotic cell derivative, It is characterized in that Prepared from apoptotic cells or apoptotic extracellular vesicles, and the supramolecular gel factor according to any one of claims 2 to 4; The apoptotic cells or extracellular vesicles contain biologically active substances with therapeutic effects; The supramolecular gelator is gelled in situ inside the apoptotic cells or apoptotic cell extracellular vesicles to form an inner core.
7. The in situ gelled apoptotic cell derivative according to claim 6, It is characterized in that The apoptotic cells or apoptotic extracellular vesicles are obtained by inducing apoptosis of mammalian cells in vitro and then separating them by centrifugation; the in vitro cells are mesenchymal stem cells, macrophages, T lymphocytes, endothelial cells, chondrocytes, or cancer cells; The ratio of the supramolecular gel factor to the apoptotic cells or apoptotic extracellular vesicles is 0.001 μmol-0.1 μmol:100 μg, preferably 0.01 μmol-0.06 μmol:100 μg, and more preferably 0.03 μmol-0.05 μmol:100 μg.
8. A method for preparing the in situ gelled apoptotic cell derivative according to claim 6 or 7, It is characterized in that The steps include: The supramolecular gel factor and the apoptotic cells or the apoptotic extracellular vesicles are incubated in a phosphate buffer to obtain the product.
9. Use of the in situ gelled apoptotic cell derivative according to claim 6 or 7 in the preparation of a drug for treating a disease, wherein the disease is a cardiovascular, skin or joint-related disease; Preferably, the disease is non-alcoholic fatty liver disease.
10. A pharmaceutical composition, It is characterized in that The invention is prepared from the in situ gelled apoptotic cell derivative according to claim 6 or 7 and pharmaceutically acceptable excipients.
